HaluGen Life Sciences Inc. in an all-stock transaction.
Entheon acquired 100% of HaluGen in exchange for 5.1 million Entheon shares.
Why Genetic Testing Is Important: Psychedelic compounds have gained significant attention in recent years for their potential to treat multiple mental health conditions including major depressive disorder, anxiety, PTSD and addiction.
However, psychedelic drugs have been found to trigger psychotic episodes in individuals with a genetic predisposition to conditions in the psychotic spectrum, like schizophrenia and bipolar I or II disorders.
HaluGen is attempting to commercialize a test to help identify genetic traits predictive of a patient’s reaction to hallucinogenic drugs. Its platform is expected to help evaluate an individual’s sensitivity and risk profile before the initiation of a treatment using psychedelic drugs.